Subbiah V, Yang D, Velcheti V, et al. State-of-the-art strategies for targeting RET-dependent cancers. J Clin Oncol. 2020;38(11):1209–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kato S, Subbiah V, Marchlik E, et al. RET aberrations in diverse cancers: next-generation sequencing of 4871 patients. Clin Cancer Res. 2017;23(8):1988–97.

Article  CAS  PubMed  Google Scholar 

Ciampi R, Nikiforov YE. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology. 2007;148(3):936–41.

Article  CAS  PubMed  Google Scholar 

Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18(3):378–81.

Article  CAS  PubMed  Google Scholar 

Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012;18(3):375–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18(3):382–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Subbiah V, Gainor JF, Rahal R, et al. Precision targeted therapy with BLU-667 for RET-driven cancers. Cancer Discov. 2018;8(7):836–49.

Article  CAS  PubMed  Google Scholar 

U.S. Food and Drug Administration, Drugs@FDA [database on the internet], GAVRETO. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213721s015lbl.pdf. Accessed 31 Jan 2025.

U.S. Food and Drug Administration, Drugs@FDA [database on the internet], GAVRETO. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213721s000lbl.pdf. Accessed 31 Jan 2025.

Gainor JF, Curigliano G, Kim DW, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol. 2021;22(7):959–69.

Article  CAS  PubMed  Google Scholar 

Subbiah V, Hu MI, Wirth LJ, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021;9(8):491–501.

Article  CAS  PubMed  Google Scholar 

Subbiah V, Cassier PA, Siena S, et al. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial. Nat Med. 2022;28(8):1640–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

European Medicines Agency, Medicines, Gavreto. https://www.ema.europa.eu/en/documents/product-information/gavreto-epar-product-information_en.pdf. Accessed 31 Jan 2025.

The China National Medical Products Administration has granted conditional approval for the marketing of Pralsetinib capsules. https://www.nmpa.gov.cn/zhuanti/ypqxgg/gggzjzh/20210324140443175.html. Accessed 31 Jan 2025.

Lin C, Wang S, Xie W, et al. The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis. Cancer Biol Ther. 2015;16(7):1019–28.

Tan AC, Seet AOL, Lai GGY, et al. Molecular characterization and clinical outcomes in RET-rearranged NSCLC. J Thorac Oncol. 2020;15(12):1928–34.

Article  CAS  PubMed  Google Scholar 

Aldea M, Marinello A, Duruisseaux M, et al. RET-MAP: an international multicenter study on clinicobiologic features and treatment response in patients with lung cancer harboring a RET fusion. J Thorac Oncol. 2023;18(5):576–86.

Article  CAS  PubMed  Google Scholar 

Griesinger F, Curigliano G, Thomas M, et al. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. Ann Oncol. 2022;33(11):1168–78.

Article  CAS  PubMed  Google Scholar 

Gild ML, Clifton-Bligh RJ, Wirth LJ, et al. Medullary thyroid cancer: updates and challenges. Endocr Rev. 2023;44(5):934–46.

Article  PubMed  PubMed Central  Google Scholar 

Lamore SD, Kohnken RA, Peters MF, et al. Cardiovascular toxicity induced by kinase inhibitors: mechanisms and preclinical approaches. Chem Res Toxicol. 2020;33(1):125–36.

Article  CAS  PubMed  Google Scholar 

Papaila A, Jacobson AT. Into the unknown: a case of new-onset cardiomyopathy in a patient treated with recently approved tyrosine kinase inhibitor, pralsetinib. Cureus. 2021;13(6):e15441.

PubMed  PubMed Central  Google Scholar 

Hou Y, Ren X, Chen Y, et al. Cardiovascular toxicities of selective ret-specific tyrosine kinase inhibitors: a pharmacovigilance study based on the United States food and drug administration adverse event reporting system database. Expert Opin Drug Saf. 2024;19:1–9.

Article  Google Scholar 

An L, Chen P, Wang J, et al. Case report: recurrent lung infections following treatment with pralsetinib for an elderly patient with RET-fusion positive NSCLC. Front Oncol. 2022;12:1024365.

Article  PubMed  PubMed Central  Google Scholar 

Lehman A, Perissinotti A, Aitken S. Cytomegalovirus viremia and hepatitis B reactivation in patient with RET fusion-positive non-small cell lung cancer treated with pralsetinib. J Oncol Pharm Pract. 2024;18:10781552241304000.

Article  Google Scholar 

Poumeaud F, Jaffrelot M, Gomez-Roca C, et al. A double-edged sword: unusual multiple severe infections with pralsetinib: a case report and literature review. Front Med. 2024;11:1402902.

Article  Google Scholar 

Lee YP, Jeong BH, Eun Y, et al. Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: a Korean single-centre compassionate use experience. Eur J Cancer. 2021;159:167–73.

Article  CAS  PubMed  Google Scholar 

Xie Y, Chen C, Huang JA. Hepatitis B virus reactivation after pralsetinib-targeted therapy in a patient with non-small cell lung cancer. Am J Ther. 2024;31(4):e494–7.

Article  PubMed  Google Scholar 

Dhital R, Paudel A, Bohra N, et al. Herbaspirillum infection in humans: a case report and review of literature. Case Rep Infect Dis. 2020;2020:9545243.

PubMed  PubMed Central  Google Scholar 

Gao M, Zhang X, Yan H, et al. Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer. Support Care Cancer. 2023;31(12):671.

Article  PubMed  PubMed Central  Google Scholar 

Ott C, Schmieder RE. Diagnosis and treatment of arterial hypertension 2021. Kidney Int. 2022;101(1):36–46.

Article  PubMed  Google Scholar